Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8343 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.8293 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8274 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.814 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.8137 |
Intermediate Similarity |
NPD2533 |
Approved |
0.8137 |
Intermediate Similarity |
NPD2534 |
Approved |
0.8137 |
Intermediate Similarity |
NPD2532 |
Approved |
0.8072 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8072 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.805 |
Intermediate Similarity |
NPD2800 |
Approved |
0.8024 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8012 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7976 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7975 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7955 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7892 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7861 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7861 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7861 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7853 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7836 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7824 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7805 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.779 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7765 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7751 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7751 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7688 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.767 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7654 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7619 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7584 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7561 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7543 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7543 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7542 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7542 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.753 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7528 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7514 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7486 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7485 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7471 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7471 |
Intermediate Similarity |
NPD919 |
Approved |
0.7459 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7455 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7423 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7423 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7421 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7414 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7391 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7386 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7381 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7337 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7326 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7317 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7308 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7303 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7299 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7284 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7283 |
Intermediate Similarity |
NPD37 |
Approved |
0.7257 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7257 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7257 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7256 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7216 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7207 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7191 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7182 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7178 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7175 |
Intermediate Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.7169 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7169 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7167 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7159 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7135 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7135 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7134 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7128 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7126 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7118 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7117 |
Intermediate Similarity |
NPD943 |
Approved |
0.7099 |
Intermediate Similarity |
NPD7985 |
Registered |
0.7093 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7093 |
Intermediate Similarity |
NPD920 |
Approved |
0.7088 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7083 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7076 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7062 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7062 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7062 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7062 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7062 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7062 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7062 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7048 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7012 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7006 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7006 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6994 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6982 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6977 |
Remote Similarity |
NPD5401 |
Approved |
0.6974 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6965 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6965 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6961 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6957 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.6954 |
Remote Similarity |
NPD1653 |
Approved |
0.695 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6915 |
Remote Similarity |
NPD7874 |
Approved |
0.6915 |
Remote Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.6914 |
Remote Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.6914 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6909 |
Remote Similarity |
NPD4060 |
Phase 1 |
0.6906 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6905 |
Remote Similarity |
NPD5404 |
Approved |
0.6905 |
Remote Similarity |
NPD5405 |
Approved |
0.6905 |
Remote Similarity |
NPD5406 |
Approved |
0.6905 |
Remote Similarity |
NPD5408 |
Approved |
0.6901 |
Remote Similarity |
NPD6190 |
Approved |
0.6891 |
Remote Similarity |
NPD6534 |
Approved |
0.6891 |
Remote Similarity |
NPD6535 |
Approved |
0.6885 |
Remote Similarity |
NPD2403 |
Approved |
0.6882 |
Remote Similarity |
NPD5953 |
Discontinued |
0.6882 |
Remote Similarity |
NPD6674 |
Discontinued |
0.6879 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD642 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.6869 |
Remote Similarity |
NPD7698 |
Approved |
0.6869 |
Remote Similarity |
NPD7697 |
Approved |
0.6869 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6868 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6842 |
Remote Similarity |
NPD7003 |
Approved |
0.6842 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6842 |
Remote Similarity |
NPD7982 |
Clinical (unspecified phase) |
0.6834 |
Remote Similarity |
NPD7870 |
Phase 2 |
0.6834 |
Remote Similarity |
NPD7871 |
Phase 2 |
0.6821 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6816 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.6812 |
Remote Similarity |
NPD4111 |
Phase 1 |
0.6812 |
Remote Similarity |
NPD4665 |
Approved |
0.6798 |
Remote Similarity |
NPD7801 |
Approved |
0.6788 |
Remote Similarity |
NPD3268 |
Approved |
0.6788 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6786 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6786 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6766 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6766 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6763 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6763 |
Remote Similarity |
NPD3300 |
Phase 2 |
0.6755 |
Remote Similarity |
NPD7240 |
Approved |
0.6752 |
Remote Similarity |
NPD7644 |
Approved |
0.6746 |
Remote Similarity |
NPD7907 |
Approved |
0.6744 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6743 |
Remote Similarity |
NPD6273 |
Approved |
0.6737 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6735 |
Remote Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.6727 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.672 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6708 |
Remote Similarity |
NPD9269 |
Phase 2 |
0.6707 |
Remote Similarity |
NPD1613 |
Approved |
0.6707 |
Remote Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.6688 |
Remote Similarity |
NPD7340 |
Approved |
0.6687 |
Remote Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.6687 |
Remote Similarity |
NPD2797 |
Approved |
0.6687 |
Remote Similarity |
NPD1203 |
Approved |
0.6687 |
Remote Similarity |
NPD411 |
Approved |
0.6684 |
Remote Similarity |
NPD4287 |
Approved |
0.6684 |
Remote Similarity |
NPD3534 |
Clinical (unspecified phase) |
0.6683 |
Remote Similarity |
NPD2493 |
Approved |
0.6683 |
Remote Similarity |
NPD2494 |
Approved |
0.6682 |
Remote Similarity |
NPD5619 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD4749 |
Approved |
0.6667 |
Remote Similarity |
NPD8319 |
Approved |
0.6667 |
Remote Similarity |
NPD1933 |
Approved |
0.6667 |
Remote Similarity |
NPD4582 |
Approved |
0.6667 |
Remote Similarity |
NPD4583 |
Approved |
0.6667 |
Remote Similarity |
NPD2344 |
Approved |
0.6667 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6667 |
Remote Similarity |
NPD8366 |
Approved |
0.6667 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.665 |
Remote Similarity |
NPD6823 |
Phase 2 |
0.6649 |
Remote Similarity |
NPD5242 |
Approved |
0.6648 |
Remote Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.6647 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6647 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6647
|
Remote Similarity |
NPD4308 |
Phase 3 |